NCT06977932 is a NA clinical trial of Carbarmazepine in Trigeminal Neuralgia, sponsored by Yuanyuan Wu.

Who is sponsoring NCT06977932?

NCT06977932 is sponsored by Yuanyuan Wu.

What drugs are being tested in NCT06977932?

Interventions in NCT06977932: Carbarmazepine, Sham Electroacupuncture, Carbarmazepine Placebo, Electroacupuncture.

What condition does NCT06977932 study?

NCT06977932 studies Trigeminal Neuralgia.

Is NCT06977932 still recruiting?

NCT06977932 is currently not yet recruiting. Last updated 5 March 2026.

Last reviewed 2026-03-05 · How we verify

NCT06977932

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Alternative Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia

Not yet recruiting NA Last updated 5 March 2026

What this trial tests

NA trial testing Carbarmazepine in Trigeminal Neuralgia in 126 participants. Not yet recruiting.

Timeline

1 March 2026

Primary endpoint
31 December 2028

31 December 2028

Quick facts

Lead sponsor	Yuanyuan Wu
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	126
Start date	1 March 2026
Primary completion	31 December 2028
Estimated completion	31 December 2028

Drugs / interventions tested

Carbarmazepine — full drug profile →
Sham Electroacupuncture
Carbarmazepine Placebo
Electroacupuncture

Conditions studied

Trigeminal Neuralgia — all drugs for Trigeminal Neuralgia →

Sponsor

Yuanyuan Wu — full company profile →

Who can join

Adults 18 to 80, any sex, with Trigeminal Neuralgia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Trigeminal neuralgia (TN), characterized by its refractory nature and recurrence, frequently leads to anxiety, depression, and insomnia, thereby significantly diminishing patients' quality of life and potentially inducing self-harm. Carbamazepine (CBZ) is the first-line medication for TN, yet it presents adverse effects such as addiction and the absence of analgesic effects upon cessation. Acupuncture, particularly electroacupuncture（EA）, has demonstrated efficacy in TN treatment, although its therapeutic outcomes are influenced by various factors. Consequently, this study aims to evaluate the clinical efficacy of EA for TN and its potential as an alternative to CBZ treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of Electroacupuncture for Trigeminal Neuralgia: Study Protocol for a Multicenter Randomized Controlled Trial.
Chen N, Xu M, Wang J, Wang D, et al · · 2026 · PMID 42261299 · DOI 10.2147/jpr.s616735
Effect of Electroacupuncture for Trigeminal Neuralgia: Study Protocol for a Multicenter Randomized Controlled Trial
Chen N, Xu M, Wang J, Wang D, et al · · 2026

Verify or expand the search:

Other recruiting trials for Trigeminal Neuralgia

Currently open trials in the same condition.

NCT07252453 — Comparison b/w Carbamazepine vs Oxcarbazepine in Treatment of Trigeminal Neuralgia · NA · active not recruiting
NCT06684275 — Comparison of Pulsed and Thermal Radiofrequency for Trigeminal Neuralgia · NA · recruiting
NCT06620172 — CT-guided vs Fluoroscopy-guided Trigeminal Ganglion Radiofrequency Thermocoagulation for Idiopathic Trigeminal Neuralgia · NA · recruiting
NCT06849219 — Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia · Phase 4 · active not recruiting
NCT06216886 — OnabotulinumtoxinA for Trigeminal Neuralgia · Phase 4 · recruiting

Other Yuanyuan Wu trials

Trials by the same sponsor.

NCT07074561 — The Synergism and Attenuation Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06977932 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yuanyuan Wu
Last refreshed: 5 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06977932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing